Company Overview
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +21.76% |
| 6 Months: | +48.92% |
| 3 Months: | +23.95% |
| 1 Month: | +107.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIVI BioVie Inc. PHARMA | 2.07 | -0.68 | $17.49M | 0.00% | -93.67% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | -54.63K | -49.93K | -57.85K | -351.35K | -357.80K | -400.53K | -662.23K | -494.81K | -691.22K | -491.43K | -500.87K | -848.29K | -706.22K | -710.45K | -699.25K | -386.75K | -3.06M | -3.00M | -5.55M | -6.67M | -5.75M | -8.83M | -11.49M | -13.77M | -10.88M | -8.78M | -7.73M | -4.12M | -7.29M | -2.99M | -5.28M | -6.26M | -5.39M |
| Net Income | -17.51K | -53.49K | -47.13K | -48.04K | -58.78K | -70.48K | -48.95K | -54.57K | -49.88K | -57.81K | -351.34K | -357.80K | -178.50K | -662.84K | -502.68K | -692.56K | - | - | - | -3.82M | 6.67M | -366.40K | 7.33M | -3.06M | -2.99M | -5.54M | -5.41M | -7.04M | -10.42M | -15.69M | -15.04M | -10.71M | -8.40M | -8.07M | -4.15M | -7.11M | -2.79M | -5.09M | -6.07M | -5.27M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.20 | -0.34 | -5.06 | 1.29 | -0.07 | -7.75 | -0.22 | -0.22 | -0.23 | -0.22 | -0.28 | -0.38 | -0.50 | -0.43 | -2.92 | -2.20 | -2.00 | -7.00 | -4.55 | -1.51 | -0.98 | -0.77 | -0.70 |
| R&D Expense | - | 11.42K | 19.15K | 19.41K | 3.40K | - | - | 0 | - | - | 127.27K | 128.56K | 120.04K | 41.85K | 186.84K | 46.42K | 194.52K | 206.02K | 331.83K | 341.50K | 346.51K | 353.20K | 100.91K | 938.10K | 789.58K | 3.09M | 4.71M | 3.58M | 6.77M | 7.03M | 11.20M | 8.88M | 6.47M | 5.70M | 1.99M | 4.70M | 1.34M | 2.94M | 4.27M | 3.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 27.25M | 45.08M | 32.18M | 18.07M |
| Operating Income | - | - | -233.38K | -432.03K | -1.55M | -2.37M | -2.50M | -2.69M | -138.05M | -27.25M | -45.08M | -32.18M | -18.07M |
| EBITDA | - | - | - | - | - | - | - | - | - | -23.69M | -45.73M | -29.00M | -16.98M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 2.16M | 4.30M | 2.89M | 332.72K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -26.08M | -50.26M | -32.12M | -17.54M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -17.51K | -321.90K | -233.01K | -431.92K | -1.33M | -2.43M | - | -16.68M | -130.25M | -26.08M | -50.26M | -32.12M | -17.54M |
| Diluted EPS | - | - | - | - | - | - | -0.98 | -6.85 | -14.82 | -106.00 | -154.70 | -73.05 | -12.12 |
| R&D Expense | - | 49.42K | 4.20K | 37.90K | 466.35K | 370.85K | 1.01M | 1.15M | 2.54M | 17.26M | 33.30M | 23.10M | 9.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 505.70K | 332.86K | 269.48K | 2.72M | 2.36M | 2.18M | 2.57M | 2.08M | 6.05M | 20.11M | 35.10M | 25.21M | 21.56M |
| Total Equity | 490.70K | 171.39K | -54.12K | 1.92M | 1.16M | 111.20K | 2.13M | -21.50M | 5.05M | 3.67M | 15.34M | 15.51M | 19.01M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | 18.64M | 19.46M | 23.84M | 17.54M |
| Long Term Debt | - | - | - | - | - | - | - | 62.50K | - | - | - | - | - |
| Total Liabilities | - | - | - | 803.25K | 1.21M | 2.06M | 443.48K | 23.58M | 996.37K | 16.44M | 19.76M | 9.70M | 2.55M |
| Current Liabilities | 15.00K | 161.47K | 323.60K | 803.25K | 630.97K | 1.24M | 443.48K | 23.52M | 996.37K | 4.17M | 14.49M | 9.35M | 2.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.51K | -172.83K | -65.38K | -153.63K | -623.62K | -621.34K | -2.50M | -1.63M | -10.45M | -18.99M | -40.25M | -27.95M | -19.03M |
| Investing Cash Flow | - | - | - | 9.91K | - | - | - | - | - | - | -14.30M | 14.53M | - |
| Financing Cash Flow | 508.21K | - | - | -5 | 505.00K | 662.00K | 2.80M | 1.33M | 14.93M | 33.12M | 55.37M | 17.80M | 12.73M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -3.6% | -187.8% | 430.5% | -22.5% | -115.0% | -2,189.0% | - | 77.6% | -2,579.0% | -710.6% | -327.6% | -207.1% | -92.3% |
| ROCE % | - | - | 431.2% | -22.5% | -89.6% | -253.1% | -117.2% | 12.6% | -2,733.6% | -170.9% | -218.7% | -202.9% | -93.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 7.16% | 605.47K | $974.81K |
| 2 | Diametric Capital, Lp | 3.04% | 256.64K | $413.18K |
| 3 | Renaissance Technologies, LLC | 1.51% | 127.92K | $205.95K |
| 4 | Citadel Advisors Llc | 1.14% | 95.95K | $154.48K |
| 5 | Geode Capital Management, LLC | 0.84% | 70.75K | $113.91K |
| 6 | Vanguard Capital Management LLC | 0.84% | 70.91K | $114.16K |
| 7 | Philadelphia Trust Company | 0.59% | 50.01K | $80.52K |
| 8 | Vanguard Fiduciary Trust Co | 0.44% | 37.56K | $60.47K |
| 9 | Jane Street Group, LLC | 0.42% | 35.86K | $57.73K |
| 10 | Prelude Capital Management LLC | 0.39% | 32.58K | $52.46K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIVI
BioVie Announces Update to Parkinson’s Phase 3 Development Program - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOYjVEdl9ta3hScVFCOWE4UDBsenV0VFh2clo4TjBBWlJQdzBUVTNLN0g5dk9OdnAyNUdna2NWNk1BdEthV2Q4U1pZSV9JdWl0ZXFsUmNYdDk0eGFReXp5UTJxaFh1ZkV6REpZa0tQdDNRcVJEd29VNG1KVEFRcEFxbzlYTTBzT1RIOWlKd0…
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFA4NDl2SS1jYTlSX1VSUVlSOFlTVTREZ1N0RW14bC1pNXlTcEFuclNpNzdJWVNiT0xEVngxWGo0NUFvTktWOWNmbw?oc=5" target="_blank">Biovie Stock Price Forecast. Should You Buy BIVI?</a> <fon…
Why BioVie (BIVI) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE9TQjF2MHltcjdIbDE5REhXMEE2ZUZFT0J4Q0lrZGZncVFJRWFlNjFZcWp2cHZ5T3pJWjRVUkc0UWNzY3pMYWRGM0F5bXdSWUVyUzViNFBYMjFBY01JeU1MTW90bEZ5VnBaYXlOYzNvNXBjN25SLW9JVFp2WE8?oc=5" target="_blank">…
BIVI Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5MeDhRNEZySmNxTk1tT21zWU9hYnRVVGJlZUFHZW05V1lPOEs2elVyMDRlNDZUeWRqc2dGMDdZVC1ETVItSzVHOUJvSHhpWVdQVlBrOUx2ODZrRXZtdUNrRy1hWHdsS3J1ZnM3RUdVb1JQSWFCSzJMLU1n?oc=5" target="_blank">BIV…
BioVie Announces Update to Parkinson’s Phase 3 Development Program - markets.businessinsider.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQeENSWUVPQzdPNUFmdld0LXplZktQZWk3ZGlDVE9Ocjd5SUg4b0RvY05YeXFuNWhTNTQ4Z3Q5aExhRTdXa05HdVJGYVlCVGFtdVl3R0tXcmVuQ3pqOWNpUWV1ZU5oR3F2ZnZMeVhTZ2ZuUGJWMVIyZnk2VnZHU0RjNXA5Y250c3pqeGx1MT…
BIVI Stock Pops As SUNRISE-PD Parkinson’s Data Fuel Hype - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE5CWVFXa292TG5uOWNQekEyNzhmbkVBdE5JeTdsV1VtLXNUQW8zYWg0NGh2NWhDejhoVUMwalUtNkdxUG9lcjlWR3lCVm80dDZmZEdzQ016aGtEMjVnTFBGTlFGZWpwaHp6S0FBNGtjNDhja1Vo?oc=5" target="_blank">BIVI Stock …
BIVI — Frequently Asked Questions
What is the current share price of BioVie Inc. (BIVI)?
As of 2026-09-19 21:16 PDT, BioVie Inc. (BIVI) trades at $2.07 on NasdaqCM. Its 52-week range is $0.96 to $2.28.
What is the market capitalisation of BIVI?
BioVie Inc. (BIVI) has a market capitalisation of $17.49M on NasdaqCM.
What is the P/E ratio of BIVI?
BIVI trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.45.
Is BIVI a good stock to buy?
This page provides a data-driven analysis of BioVie Inc. (BIVI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.